EGIS 8858

Drug Profile

EGIS 8858

Latest Information Update: 16 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Egis Pharmaceuticals
  • Developer Servier
  • Class Anxiolytics; Benzodiazepines; Neuroprotectants; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders

Most Recent Events

  • 02 Oct 2002 A preclinical study has been added to the adverse events and Anxiety Disorders pharmacodynamics sections
  • 28 Jul 2000 A preclinical study has been added to the Anxiety Disorders pharmacodynamics section
  • 30 Nov 1999 Preclinical development for Anxiety disorders in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top